Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ELTX

Elicio Therapeutics (ELTX) Stock Price, News & Analysis

Elicio Therapeutics logo

About Elicio Therapeutics Stock (NASDAQ:ELTX)

Advanced Chart

Key Stats

Today's Range
$5.13
$5.75
50-Day Range
N/A
52-Week Range
N/A
Volume
19,242 shs
Average Volume
57,512 shs
Market Capitalization
$59.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Buy

Company Overview

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.

Elicio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ELTX MarketRank™: 

Elicio Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 779th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Elicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Elicio Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Elicio Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Elicio Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Elicio Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Elicio Therapeutics has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.95% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving.
  • Dividend Yield

    Elicio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Elicio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.95% of the float of Elicio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Elicio Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Elicio Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving.
    • Insider Buying vs. Insider Selling

      In the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 35.03% of the stock of Elicio Therapeutics is held by institutions.

    • Read more about Elicio Therapeutics' insider trading history.
    Receive ELTX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    ELTX Stock News Headlines

    Elicio Therapeutics reports FY24 EPS ($4.25) vs ($6.96) last year
    Buffett’s favorite chart just hit 209% – here’s what that means for gold
    A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
    JonesTrading Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)
    See More Headlines

    ELTX Stock Analysis - Frequently Asked Questions

    Elicio Therapeutics, Inc. (NASDAQ:ELTX) posted its quarterly earnings data on Monday, March, 31st. The company reported ($1.02) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by $0.08.

    Elicio Therapeutics (ELTX) raised $40 million in an initial public offering (IPO) on the week of July 26th 2021. The company issued 3,100,000 shares at a price of $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. acted as the underwriters for the IPO and National Securities Corp. was co-manager.

    Top institutional investors of Elicio Therapeutics include Moody Lynn & Lieberson LLC (0.09%).
    View institutional ownership trends
    .

    Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA).

    Company Calendar

    Last Earnings
    3/31/2025
    Today
    5/04/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    N/A
    Current Symbol
    NASDAQ:ELTX
    Fax
    N/A
    Employees
    N/A
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $10.00
    High Stock Price Target
    $10.00
    Low Stock Price Target
    $10.00
    Potential Upside/Downside
    +81.8%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-35,190,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $2.30 million
    Price / Cash Flow
    N/A
    Book Value
    $1.35 per share
    Price / Book
    4.07

    Miscellaneous

    Free Float
    7,699,000
    Market Cap
    $59.35 million
    Optionable
    Not Optionable
    Beta
    0.77
    20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

    Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

    Get This Free Report

    This page (NASDAQ:ELTX) was last updated on 5/4/2025 by MarketBeat.com Staff
    From Our Partners